Using AI to develop personalised care for people with breast cancer

What’s the project about?

Researchers are developing a clinical study to look at whether an AI app can measure changes in quality of life for some people living with or beyond breast cancer. This could include giving people information about treatment, medication reminders, or tips on managing side effects.

They hope that this can help healthcare professionals make care more personalised for people diagnosed with cancer.

They want to make sure that the app is usable and useful for people diagnosed with cancer. They’d like to hear from people about what would make the app most useful for them.

Who can take part?

You can take part if you’ve been diagnosed with breast cancer and are taking any of the following medication: 

• Abemaciclib (Verzenio)
• Palbociclib (Ibrance)
• Ribociclib (Kisqali)

• Tamoxifen

• Fulvestrant (faslodex)

• Letrozole (femara)

• Anastrozole (arimidex)

• Exemestane (aromasin)

• Pertuzumab and trastuzumab (phesgo)

• Capivasertib (Truqap)

• Capecitabine (Xeloda)

Why do you want me to be involved?

By taking part you can make sure that the needs and priorities of people with breast cancer are at the centre of the app’s design and development.

By having a useful and relevant app, the researchers hope to be able to offer healthcare professionals and people with breast cancer an effective tool to personalise cancer care and improve quality of life.

What will you ask me to do?

The researchers would like you to test the app over a weekend. You’ll have a short 15 minute call on a Friday to set up the app, and then you’ll use the app over the weekend.

You’ll then be invited to a 1-hour focus group the following Monday where you can give feedback on the app and give suggestions for future features.

The dates are yet to be confirmed, but there is the possibility for flexibility on which weekend you participate on.